Current Report Filing (8-k)
14 Novembro 2022 - 10:02AM
Edgar (US Regulatory)
BIOCEPT INC false 0001044378 0001044378
2022-11-10 2022-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10,
2022
BIOCEPT,
INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36284 |
|
80-0943522 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
9955 Mesa Rim Road, San
Diego, CA |
|
92121 |
(Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858)
320-8200
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Securities Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per
share |
|
BIOC |
|
The Nasdaq Stock Market
LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 |
Results of Operations and Financial Condition.
|
On November 10, 2022, we issued a press release announcing our
financial results for the three months ended June 30, 2022. A
copy of the press release and accompanying information is attached
as Exhibit 99.1 to this current report.
The information in this Item 2.02, and Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that
Section. The information in this current report shall not be
incorporated by reference into any registration statement or other
document filed with the Securities and Exchange Commission, whether
filed before or after the date hereof regardless of any general
incorporation language in any such filing, unless we expressly set
forth in such filing that such information is to be considered
“filed” or incorporated by reference therein.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Biocept, Inc. |
|
|
|
|
Date: November 14, 2022 |
|
|
|
By: |
|
/s/ Samuel D. Riccitelli
|
|
|
|
|
|
|
Samuel D. Riccitelli |
|
|
|
|
|
|
Interim President and Chief
Executive Officer |
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Jan 2023 até Fev 2023
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Fev 2022 até Fev 2023